New hope for GVHD patients: ruxolitinib tested as First-Line therapy
NCT ID NCT06660355
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 31 times
Summary
This study compares two drugs, ruxolitinib and prednisone, as the first treatment for chronic graft-versus-host disease (cGVHD), a complication after bone marrow transplant. About 120 adults who need systemic therapy for cGVHD will be randomly assigned to receive one of the two drugs. The goal is to see if ruxolitinib works better than the standard steroid treatment at controlling the disease without needing additional therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
-
Univ of Miami - Sylvester Comprehensive Cancer Center
RECRUITINGMiami, Florida, 33136, United States
Contact
-
University of Kansas Cancer Center
RECRUITINGKansas City, Kansas, 66160, United States
Contact
-
University of Virginia Comprehensive Cancer Center
RECRUITINGCharlottesville, Virginia, 22908, United States
Contact
-
Virginia Commonwealth University
RECRUITINGRichmond, Virginia, 23219, United States
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.